Back to Search
Start Over
Experts call for better management of blood glucose in hospitalized patients.
- Source :
-
American Journal of Health-System Pharmacy . 3/15/2006, Vol. 63 Issue 6, p488. 4p. - Publication Year :
- 2006
-
Abstract
- Purpose. The role of trastuzumab in adjuvant therapy for locally invasive breast cancer is discussed. Summary. Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor-2 (HER2). Currently, trastuzumab is indicated for use in HER2-positive patients with metastatic breast cancer. Because trastuzumab specifically targets a receptor that is overexpressed in tumor cells, it is less likely to cause the cytotoxic adverse effects of traditional chemotherapy. Cardiotoxicity has been a major concern, however. Several trials were started to evaluate trastuzumab in the adjuvant setting in patients diagnosed with early-stage breast cancer. The interim results of these trials have shown a promising effect of adjuvant therapy with trastuzumab in improving overall survival, disease-free survival, relapse-free survival, and distant-disease-free survival. Conclusion. The use of trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer can lead to increased survival. The appropriateness of trastuzumab therapy should be considered based on HER2 status, cost, and risk of toxicity. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10792082
- Volume :
- 63
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- American Journal of Health-System Pharmacy
- Publication Type :
- Academic Journal
- Accession number :
- 20082505
- Full Text :
- https://doi.org/10.2146/news050057